DE122010000015I1 - Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten - Google Patents

Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten

Info

Publication number
DE122010000015I1
DE122010000015I1 DE122010000015C DE122010000015C DE122010000015I1 DE 122010000015 I1 DE122010000015 I1 DE 122010000015I1 DE 122010000015 C DE122010000015 C DE 122010000015C DE 122010000015 C DE122010000015 C DE 122010000015C DE 122010000015 I1 DE122010000015 I1 DE 122010000015I1
Authority
DE
Germany
Prior art keywords
antigens
vaccines containing
combined vaccines
containing hepatitis
surface antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE122010000015C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122010000015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE122010000015I1 publication Critical patent/DE122010000015I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE122010000015C 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten Pending DE122010000015I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine

Publications (1)

Publication Number Publication Date
DE122010000015I1 true DE122010000015I1 (de) 2010-07-08

Family

ID=26300928

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69334297T Expired - Lifetime DE69334297D1 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DE122010000015C Pending DE122010000015I1 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
DE69319728T Revoked DE69319728T2 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DE122010000016C Pending DE122010000016I1 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69334297T Expired - Lifetime DE69334297D1 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69319728T Revoked DE69319728T2 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DE122010000016C Pending DE122010000016I1 (de) 1992-05-23 1993-05-15 Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten

Country Status (31)

Country Link
US (1) US6013264A (de)
EP (4) EP2156845A1 (de)
JP (1) JP3626996B2 (de)
KR (1) KR100287083B1 (de)
CN (2) CN1136918C (de)
AP (1) AP567A (de)
AT (2) ATE168271T1 (de)
AU (5) AU4315693A (de)
CA (1) CA2136429C (de)
CY (1) CY2614B2 (de)
CZ (1) CZ283910B6 (de)
DE (4) DE69334297D1 (de)
DK (2) DK0835663T3 (de)
ES (2) ES2334181T3 (de)
FI (1) FI945483A (de)
HK (2) HK1021142A1 (de)
HU (1) HU220236B (de)
IL (1) IL105770A (de)
LU (2) LU91658I2 (de)
MA (1) MA22894A1 (de)
MX (1) MX9302982A (de)
MY (1) MY110665A (de)
NO (1) NO309675B1 (de)
NZ (1) NZ253065A (de)
PT (1) PT835663E (de)
RU (1) RU2160120C2 (de)
SG (1) SG48365A1 (de)
SI (1) SI9300271A (de)
SK (1) SK280702B6 (de)
UA (1) UA40596C2 (de)
WO (1) WO1993024148A1 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
KR100425929B1 (ko) 1995-06-23 2004-05-31 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄포스페이트상에흡착된다당류컨쥬게이트항원을포함하는백신조성물
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
CN100408095C (zh) * 1996-07-02 2008-08-06 康诺特实验室有限公司 多价dtp-polio疫苗
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
EP1588714A2 (de) 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Adjuvanzsysteme und Impfstoffe
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
ES2544979T3 (es) 2001-01-23 2015-09-07 Sanofi Pasteur Inc. Vacuna de conjugado de polisacárido-CRM197 meningocócica tri- o tetravalente
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2003224017A1 (en) * 2002-03-28 2003-10-13 Brenntag Biosector A/S Combined dna/protein vaccine compositions
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
AR041881A1 (es) 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Procedimiento de secado para la obtencion de un liquido altamente viscoso que conserva la antigenicidad o actividad de una agente activo y vacuna obtenida a partir de el
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2277538A1 (de) 2003-10-02 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Kombinationsimpfstoffe gegen Meningitis
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
CA2568364C (en) 2004-06-04 2013-10-15 Rachel Schneerson Methods for preparing immunogenic conjugates
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
EP2201961B1 (de) 2005-06-27 2018-01-24 GlaxoSmithKline Biologicals S.A. Immunologische Zusammensetzung
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
SG178761A1 (en) * 2007-02-07 2012-03-29 Sigma Tau Ind Farmaceuti Recombinant antigens of human cytomegalovirus (hcmv)
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
KR101993431B1 (ko) 2011-01-06 2019-06-26 바이오노르 이뮤노 에이에스 단량체형 및 다량체형 면역원성 펩타이드
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
MX2013013185A (es) * 2011-05-11 2014-06-05 Riesbeck Healthcare Sweden Ab Proteina f, una nueva adhesina de haemophilus influenzae con propiedades de unión a la laminina y vitronectina.
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (de) 2011-11-11 2013-05-15 Novartis AG Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
CA2862560A1 (en) 2012-02-01 2013-08-08 Glaxosmithkline Biologicals S.A. Fermentation process for bordetella species
US20150125486A1 (en) * 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
EA201492262A1 (ru) 2012-06-06 2015-08-31 Бионор Иммуно Ас Конструкция пептидного каркаса
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
BR112015008040A2 (pt) 2012-10-12 2017-07-04 Glaxosmithkline Biologicals Sa composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina
EP2863943B1 (de) 2013-03-08 2016-07-13 Crucell Holland B.V. Nicht zellulärer pertussis-impfstoff
WO2014164727A1 (en) 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
JP6564367B2 (ja) 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
MA42317B2 (fr) * 2015-09-16 2021-11-30 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
EP4070815A1 (de) 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1-env-fusionspeptid-immunogene und deren verwendung
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405A1 (de) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Glycanmaskierte manipulierte äussere domänen von hiv-1 gp120 und deren verwendung
SG11202000224SA (en) 2017-07-18 2020-02-27 Serum Inst Of India Pvt Ltd An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020043874A1 (en) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020086483A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
GB2599572B (en) 2019-05-20 2023-09-20 Soligenix Inc Compositions and methods of manufacturing trivalent filovirus vaccines
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
WO2022224966A1 (ja) * 2021-04-20 2022-10-27 Ｋｍバイオロジクス株式会社 ６種混合液状ワクチン組成物
CA3228275A1 (en) 2021-08-03 2023-02-09 Genoveffa Franchini Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
EP0278940A3 (de) 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis-B-Virus-Oberflächenantigene und sie enthaltende hybride Antigene
EP1088830A3 (de) 1987-06-22 2004-04-07 Medeva Holdings B.V. Partikel von Hepatitis B Oberflächenantigen
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Proz & Prod Gmbh DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
ATE159031T1 (de) 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
CY1934A (en) 1989-11-06 1990-11-01 Smithkline Beecham Biolog Process
ATE129159T1 (de) 1990-02-12 1995-11-15 Smithkline Beecham Biolog Impfstoff.
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) * 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt
AU685443B2 (en) * 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
KR100425929B1 (ko) 1995-06-23 2004-05-31 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄포스페이트상에흡착된다당류컨쥬게이트항원을포함하는백신조성물
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Also Published As

Publication number Publication date
EP0835663B1 (de) 2009-09-30
CN1136918C (zh) 2004-02-04
IL105770A0 (en) 1993-09-22
EP2289548A2 (de) 2011-03-02
EP0835663A2 (de) 1998-04-15
SK142194A3 (en) 1995-08-09
AU2010200249A1 (en) 2010-02-11
KR100287083B1 (ko) 2001-04-16
NZ253065A (en) 1996-10-28
AP9300530A0 (en) 1993-07-31
AU709406C (en) 2004-04-08
RU2160120C2 (ru) 2000-12-10
JPH07508267A (ja) 1995-09-14
AU2010200249B2 (en) 2012-01-12
RU94046145A (ru) 1997-03-27
WO1993024148A1 (en) 1993-12-09
HU9403366D0 (en) 1995-02-28
CZ289294A3 (en) 1995-09-13
DK0835663T3 (da) 2010-02-01
HUT71791A (en) 1996-02-28
MY110665A (en) 1999-01-30
SK280702B6 (sk) 2000-06-12
SI9300271A (en) 1993-12-31
EP0642355B1 (de) 1998-07-15
NO944475D0 (no) 1994-11-22
IL105770A (en) 1998-08-16
DE69334297D1 (de) 2009-11-12
AU1648097A (en) 1997-05-29
DE69319728T2 (de) 1999-02-04
NO309675B1 (no) 2001-03-12
DE69319728D1 (de) 1998-08-20
AU5062902A (en) 2002-08-08
CA2136429C (en) 2001-12-11
LU91658I2 (fr) 2010-05-03
AP567A (en) 1996-11-25
FI945483A (fi) 1995-01-20
JP3626996B2 (ja) 2005-03-09
ES2118963T3 (es) 1998-10-01
CN1623602A (zh) 2005-06-08
NO944475L (no) 1995-01-18
EP2289548A3 (de) 2012-08-08
SG48365A1 (en) 1998-04-17
ATE444079T1 (de) 2009-10-15
AU785433B2 (en) 2007-05-31
HU220236B (hu) 2001-11-28
AU4315693A (en) 1993-12-30
CN1085450A (zh) 1994-04-20
MX9302982A (es) 1993-12-01
LU91659I2 (fr) 2010-05-03
ES2334181T3 (es) 2010-03-05
ATE168271T1 (de) 1998-08-15
AU709406B2 (en) 1999-08-26
EP0642355A1 (de) 1995-03-15
DK0642355T3 (da) 1998-11-30
US6013264A (en) 2000-01-11
CZ283910B6 (cs) 1998-07-15
MA22894A1 (fr) 1993-12-31
CY2614B2 (en) 2012-01-25
HK1021142A1 (en) 2000-06-02
CA2136429A1 (en) 1993-12-09
EP2156845A1 (de) 2010-02-24
KR950701822A (ko) 1995-05-17
PT835663E (pt) 2010-01-04
AU2007201162A1 (en) 2007-04-19
UA40596C2 (uk) 2001-08-15
CN1313152C (zh) 2007-05-02
HK1011290A1 (en) 1999-07-09
EP0835663A3 (de) 1999-03-03
FI945483A0 (fi) 1994-11-22
DE122010000016I1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
DE122010000015I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
PT86640A (pt) Hepatitis b virus surface antigens and hybrid antigens containing them
EP0362332A4 (en) Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
EP0359063A3 (en) Antibody having high affinity to hapten as antigen and immunogen for obtaining the same
IL70746A0 (en) Specific cea-family antigens,antibodies specific thereto and methods for the use thereof
EP0485476A4 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
GB2267148B (en) Footrot antigens,vaccines and diagnostic assays
EP0547631A3 (en) Antibody expression vector and antibodies produced thereby
ZA945696B (en) Novel Eimeria antibodies and antigens and methods of using the same
GB2238959B (en) Antigen and conjugates thereof for suppressing immune response
GB9021286D0 (en) Antigens and antibodies thereto their uses
IL104291A0 (en) Antigenic epitopes and antibodies against them
AU4996193A (en) Pfemp3 malaria antigen, analogs, antibodies and uses thereof
IL104767A0 (en) Antigenic epitopes and antibodies against them
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.
IE880242L (en) Hepatitis b virus antigens.
ATE112855T1 (de) Verfahren und zusammensetzungen betreffend regressions-assoziierte antigene.
IE892694L (en) Monoclonal antibody against hiv virus
BR1100913A (pt) Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos
IE880458L (en) Virus antigen